Neurorx, Inc., Corporation just submitted form D announcing $2.16 million equity financing. This is a new filing. Neurorx was able to finance itself with $2.16 million. That is 100.00% of the financing offer. The total offering amount was $2.16 million. The private financing document was filed on 2016-11-21. The reason for the financing was: All amounts sold were sold in a previous convertible note offering. Most note holders have converted their convertible notes to equity in this offering..
Neurorx is based in New Jersey. The company’s business is Pharmaceuticals. The SEC form was filed by Jonathon Pelter Authorized Signatory. The company was incorporated in 2015. The filler’s address is: 1201 Orange Street, Suite 600, One Commerce Center, Wilmington, De, Delaware, 19801. Jonathan Javitt is the related person in the form and it has address: 913 North Market Street, Suite 200, C/O Neurorx, Inc., Wilmington, De, Delaware, 19801. Link to Neurorx Filing: 000167976816000003.
Analysis of Neurorx Offering
On average, startups in the Pharmaceuticals sector, sell 60.90% of the total offering amount. Neurorx sold 100.00% of the offering. Could this mean that the trust in Neurorx is high? The average investment offering size for companies in the Pharmaceuticals industry is $556,000. The total amount raised is 288.43% bigger than the average for companies in the Pharmaceuticals sector. The minimum investment for this financing was set at $1500. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Neurorx Also
The Form D signed by Jonathon Pelter might help Neurorx, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.